Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.

Suresh S.  Ramalingam

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Loxo; Merck; Nektar; Takeda; Tesaro

Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)

Travel, Accommodations, Expenses - AstraZeneca

Tudor Eliade  Ciuleanu

Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Ipsen; Janssen; MSD; Pfizer; Roche; Sanofi; SERVIER

Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Ipsen; Janssen; MSD; Pfizer; Roche; Sanofi; SERVIER

Adam  Pluzanski

Speakers' Bureau - Bristol-Myers Squibb

Expert Testimony - Bristol-Myers Squibb

Travel, Accommodations, Expenses - Bristol-Myers Squibb

Jong-Seok  Lee

No Relationships to Disclose

Michael  Schenker

Research Funding - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Pfizer/EMD Serono; Roche

Travel, Accommodations, Expenses - Bristol-Myers Squibb

Reyes  Bernabe Caro

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Roche; Takeda

Ki Hyeong  Lee

Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD

Bogdan  Zurawski

No Relationships to Disclose

Clarisse  Audigier-Valette

Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Lilly; Novartis; Pfizer; Roche

Mariano  Provencio

No Relationships to Disclose

Helena  Linardou

Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Roche; Takeda

Speakers' Bureau - AstraZeneca

Sang-We  Kim

No Relationships to Disclose

Hossein  Borghaei

Honoraria - Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; HUYA Bioscience International; Lilly; Merck; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda; Trovagene

Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)

Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis

Other Relationship - Incyte; Takeda; University of Pennsylvania

Matthew David  Hellmann

Stock and Other Ownership Interests  - Immunai; Shattuck Labs

Honoraria - AstraZeneca; Bristol-Myers Squibb

Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Nektar; Shattuck Labs; Syndax

Research Funding - Bristol-Myers Squibb (Inst)

Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb

Kenneth John  O'Byrne

Stock and Other Ownership Interests  - CARP Pharmaceuticals

Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer/EMD Serono; Roche; Teva

Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Merck Sharp & Dohme; Natera; Novartis; Pfizer; Roche/Genentech; Teva

Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Janssen-Cilag; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Roche

Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb

Patents, Royalties, Other Intellectual Property - I am named on 4 patents/provisional patents held by the University of Queensland (Inst)

Travel, Accommodations, Expenses - boehringer Ingelheim; Bristol-Myers Squibb; Roche

Luis G.  Paz-Ares

Leadership - Altum Sequencing; European Medicines Agency (I); Genomica

Honoraria - Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Sysmex

Research Funding - AstraZeneca; Bristol-Myers Squibb

Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda

Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)

Martin  Reck

Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech

Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech

Faith Ellen  Nathan

Employment - Bristol-Myers Squibb

Stock and Other Ownership Interests  - AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson; Lilly

Julie R.  Brahmer

Honoraria - Roche/Genentech

Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; Janssen Oncology; Lilly; Merck; Syndax

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Revolution; Spectrum Pharmaceuticals (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech

Other Relationship - Bristol-Myers Squibb; Janssen Oncology; merck